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Summary 
The S. cerevisiae Cdc13 is a multi-functional protein with key roles in 
regulation of telomerase, telomere end protection, and conventional telomere 
replication, all of which are cell cycle-regulated processes. Given that 
phosphorylation is a key mechanism for regulating protein function, we identified 
sites of phosphorylation using nano liquid chromatography-tandem mass 
spectrometry (nanoLC-MS/MS). We also determined phosphorylation abundance 
on both wild type (WT) and a telomerase deficient form of Cdc13, encoded by the 
cdc13-2 allele, in both G1 phase cells, when telomerase is not active, and G2/M 
phase cells, when it is. We identified 21 sites of in vivo phosphorylation, of which 
only five had been reported previously. In contrast, phosphorylation of two in vitro 
targets of the ATM-like Tel1 kinase, S249 and S255, was not detected. This 
result helps resolve conflicting data on the importance of phosphorylation of 
these residues in telomerase recruitment. Multiple residues showed differences 
in their cell cycle pattern of modification. For example, phosphorylation of S314 
was significantly higher in G2/M compared to G1 phase and in WT versus mutant 
Cdc13, and a S314D mutation negatively affected telomere length. Our findings 
provide new targets in a key telomerase regulatory protein for modulation of 
telomere dynamics. 
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INTRODUCTION 
The telomere is a nucleoprotein structure that caps the end of linear 
chromosomes and is essential for preserving genome integrity. Saccharomyces 
cerevisiae telomeric DNA is composed of ~300 bp of degenerate TG1-3 repeats, 
which are maintained by the enzyme telomerase.1 The minimal components for 
in vitro telomerase activity are Est2, the reverse transcriptase subunit,2 and 
TLC1, the RNA template for G-rich strand synthesis.3 Three other proteins are 
also required for in vivo telomerase action: Cdc13, the telomeric single strand 
(ss) DNA binding protein,4,5 Est1, the recruiter-activator of telomerase,6-8 and 
Est3, an accessory subunit of unknown function.7  
Telomere replication is regulated by both the cell cycle and telomere length. 
Semi-conservative replication of telomeric DNA and telomere lengthening via 
telomerase occur only during late S-G2 phase.9,10 Since telomerase activity is 
present throughout most of the cell cycle, current models propose that substrate 
accessibility is the rate-liming step for telomerase action. Telomerase recruitment 
to telomeres in late S/G2 phase depends on a specific interaction between 
Cdc13 and Est1.11-14 Telomeric C-strand degradation, which generates long ss 
G-tails, the presumed substrates for telomerase action, is also limited to late 
S/G2 phase.1 As in mammals, short telomeres are preferentially elongated.15 
Est2 and Est1 both bind preferentially to short telomeres.16-18  
Like many cellular processes, telomere replication is regulated at least in part 
by phosphorylation. Cyclin-dependent kinase 1 (CDK1) is required for cell cycle 
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regulated C-strand degradation19,20 while telomere length is strongly dependent 
on the kinase activity of Tel1, the yeast homolog of ataxia-telangiectasia mutated 
(ATM) (and to a lesser extent on Mec1, the homolog of AT-related or ATR).21,22 
Tel1 itself binds preferentially to short telomeres and its activity is important for 
preferential lengthening of short telomeres.16,23,24 An important step in 
determining mechanisms of telomere length control is to identify the telomere 
relevant targets of these kinases.  
Cdc13, which binds to telomeric ssDNA with high affinity and sequence 
specificity,4,5,25 is a crucial player in regulating telomere replication. It is essential 
for telomerase action in vivo as a single amino acid mutation at position 252, the 
cdc13-2 allele, can lead to a telomerase null phenotype.5 It is also required for 
telomere end protection as removing Cdc13 leads to rapid telomere degradation 
and activation of a DNA damage checkpoint that arrests cells in G2/M phase.26 In 
addition to binding telomeric ssDNA, Cdc13 forms a homodimer27,28 and 
associates with a number of nuclear proteins important in maintaining telomere 
structure and telomerase activity. Cdc13 binding to Est1 through a genetically 
and biochemically defined telomerase recruitment domain (RD) is essential for 
G-strand elongation by telomerase.12,13,14 The interaction between Cdc13 and 
Pol1, the largest subunit of DNA polymerase !, is implicated in C-strand 
synthesis by the conventional replication machinery.29,30 Cdc13 also forms a 
complex with Stn1 and Ten1, proteins essential for telomere end protection.31-33 
Genetic evidence suggests that these interactions compete with each other for 
the execution of different functions of Cdc13. For example, mutations that reduce 
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Cdc13-Pol129 or Cdc13-Stn131,33,34 interaction lead to long telomeres, while 
overexpression or telomere-tethering of STN1 result in telomere shortening.35 
The importance of Cdc13 in telomere dynamics makes it an ideal target for 
phosphorylation-dependent regulation. Cdc13 can be phosphorylated in vitro and 
in vivo by Tel1, Mec1, and CDK1 kinases.36-38 Simultaneous mutation of two of 
the in vitro targets of Tel1/Mec1 within the RD of Cdc13, S249A and S255A, 
eliminates telomerase mediated telomere lengthening.36 These observations 
suggest that phosphorylation of Cdc13 by Tel1/Mec1 at these residues is critical 
for telomerase recruitment in vivo. However, a different disruption in the 
Tel1/Mec1 motifs (Q250A Q256A) does not render the cell telomerase 
deficient,39 raising the concern that S249 and S255 may not be in vivo targets of 
Tel1/Mec1 kinases. Mutation of the CDK1 target, T308A, leads to modestly 
shorter telomeres and reduces Est1 telomere binding.37,38 Mec1 phosphorylation 
of S306 does not affect telomere length but suppresses de novo telomere 
addition at DNA double strand breaks (DSBs).40 To date, it is not known if Cdc13 
is subject to modification by other kinases. 
Here we report a comprehensive analysis of Cdc13 phosphorylation using 
mass spectrometric and genetic approaches. In addition to confirming previously 
reported sites, we identified 16 novel phosphorylation sites on Cdc13. To 
determine the importance of these modifications, we employed a label-free 
quantitative approach to identify residues that are differentially phosphorylated as 
a function of cell cycle stage and/or between wild type (WT) Cdc13 and the 
telomerase defective mutant protein encoded by cdc13-2. These studies reveal a 
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novel phosphorylation site that was enriched in G2 phase on WT Cdc13 and that 
negatively modulated telomere length in vivo. 
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METHODS  
Protein purification 
WT and the E252K mutant of Cdc13, as well as protein fragments, were over-
expressed in S. cerevisiae and purified as described.14 For cell cycle-arrested 
cultures, cells were induced for Cdc13 over-expression first for ~8 hr before 
addition of ! factor (20 ng/mL) or nocodazole (Sigma-Aldrich, 15 µg/mL). Cells 
were grown for another 3.5 hr before harvesting. Cell cycle distributions were 
determined by flow cytometry. 
 
MS and MS/MS analysis 
Purified Cdc13 proteins were treated with 5 mM dithiothreitol (DTT) at 51oC 
for 1 hr to reduce disulfide bounds. The cysteines were then alkylated by treating 
with 14 mM iodoacetamide in the dark at room temperature for 45 min, as 
previously described.41 The resulting proteins were enzymatically digested using 
either trypsin (Promega, 1:100 weight) or LysC (Roche, 1:5 weight), and desalted 
prior to mass spectrometry (MS) analysis as previously described.42 Alternatively, 
purified proteins were subject to thiol reduction, alkylation, and trypsin digestion 
according to the FASP methodology.43  
Approximately 5 µg of sample was loaded by an autosampler (AS-2; Eksigent 
Technologies Inc., CA, USA) onto a 75 µm fused silica capillary column with an 
ESI tip that was hand-packed with 130 mm of C18 reverse phase resin (5 µm 
particles, 200 Å pore size). Samples were chromatographically resolved using a 
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110 minute 1-100% buffer B gradient (buffer A = 0.1 mol/L acetic acid, buffer B = 
95% acetonitrile in 0.1 mol/L acetic acid) at a flow rate of approximately 200-300 
nL/min controlled by an HPLC pump (1200 series; Agilent, Santa Rosa, CA, 
USA). The HPLC effluent was coupled directly to an LTQ-Orbitrap XL hybrid 
mass spectrometer (ThermoFisher Scientific, Carlsbad, CA, USA) with a 
resolution of 30,000 for full MS followed by seven data-dependent and targeted 
MS/MS acquisitions, alternating between CID and ETD fragmentation (ETD 
reaction time of 100ms, ETD activation time of 100ms, activation Q of 0.25).    
 
Method for phosphorylation site identification and relative quantitation 
A traditional “shotgun” nanoLC-MS/MS approach based on identification and 
subsequent quantification of PTMs would not be appropriate for the purpose of 
this experiment. Most of the phosphorylation sites on Cdc13 are present on 
peptides that can be modified on more than one residue, and tandem mass 
spectra of these modified isoforms share a significant number of fragment ion 
peaks, resulting in a large number of false positive identifications by traditional 
tandem MS search algorithms. In addition, the relative concentrations of modified 
isoforms can span orders of magnitudes (e.g., 100 copies of site 1 
phosphorylation are present for every copy of site 2 phosphorylation). Therefore, 
tandem MS is often not available for lower abundance isoforms since MS2 
events are often triggered by the largest signals in data-dependent MS2 
acquisition, creating false negativity for the low abundance phosphorylation 
events due to undersampling.  
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In order to address these problems, we developed an algorithm that 
incorporates MS, MS/MS and chromatographic information into the PTM 
identification and quantitation. The advantage of this approach is that we can 
confidently assign a signal to a particular PTM based on its LC retention time and 
MS isotopic distribution even when MS/MS data are not available. Low 
abundance PTMs identified in this fashion were subsequently targeted for MS2 
fragmentation in later runs to confirm the assignments. In addition, all MS2 
identifications were extensively manually to ensure site localization accuracy 
(tandem MS annotations for the phosphorylation sites identified are provided in 
Supplementary Figure 1). As summarized in Figure 2, our method uses a 
mathematical model that simultaneously identifies and quantitates all modified 
isoforms of a single peptide sequence by maximizing (1) the fit between the 
experimental and theoretical isotopic distributions of each modified isoform in the 
MS and (2) the number of observed fragment ion peaks that support the modified 
isoform in any available MS2. This objective function is solved with respect to 
constraints that restrict modified isoform assignments to be chromatographically 
feasible. Specifically, under our acidic mobile phase conditions, phosphorylation 
of a residue on a peptide generally results in that modified isoform becoming 
more hydrophobic than its non-phosphorylated counterpart. Thus, all 
identifications are required to satisfy these temporal relationships based on their 
relative chemicophysical properties. The model also enforces the constraint that 
multiple charge states of the same modified isoform should co-elute. Lastly, 
because several phosphorylation sites were in close proximity of arginines and 
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lysines clusters (i.e., ‘RK’, ‘KRKRK’, ‘KK’, etc.) and we often observed alternative 
cleavage patterns with Lys-C and trypsin, missed cleavages were allowed in the 
in silico digest of the Cdc13 protein sequence. 
  To illustrate the concept behind the proposed method, consider the 
theoretical peptide presented in lower left of Figure 2, which has two possible 
sites of phosphorylation (denoted by the gray circles).  We see that two peaks in 
the MS potentially correspond to the modified isoform with two phoshorylations, 
three peaks in the MS potentially correspond to the modified isoform with one 
phoshorylation, and two peaks are potentially correspond to the unmodified state 
of the peptide (i.e. unphosphorylated).   The goal of the proposed model is to 
assign one (or none) of these MS peaks to each modified form.  When 
considering the assignment of a MS peak to a particular modified peptide, it is 
important that the observed experimental MS isotopic distribution (i.e., 
monoisotopic peak, +1 isotope, and +2 isotope) of the peptide resembles its 
theoretical isotopic distribution, which can be approximated by the Euclidean 
distance between the two profiles.  Also, if a tandem MS is available for any of 
the potential candidate MS peaks, its fragment ions should support the amino 
acid sequence and postulated sites of phosphorylation of the modified form 
under consideration.    The combined evidence that the experimental MS isotopic 
distribution and tandem MS of a given MS peak explains a particular modified 
form is simultaneously balanced against the constraint that the final MS peaks 
assigned to these three modified peptides must be chromatographically 
consistent (i.e., the unmodified peptide elutes first, the mono-phosphorylated 
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peptide elutes second, and the di-phosphorylated peptide elutes last, as 
illustrated in Figure 2).  By formulating this problem as an optimization problem, 
we are able to simultaneously consider these modes of information when 
assigning MS peaks to the possible modified forms.  
The MS signal was used to estimate the relative abundance of the each 
modified form.  Specifically, for a given modified form we integrated the MS 
signal over all isotopic peaks (i.e., monoisotopic, +1 and +2 isotopes) and across 
all observed charge states, including the contributions from exogenous 
modifications introduced during sample processing such as oxidized methionine 
and carbamidomethylation of cysteine.  This abundance was then normalized to 
100% relative signal by diving by the summation of the abundances for all 
modified forms of the same peptide.  Several technical and biological replicates 
were examined to provide quantitative estimates of cell cycle specific changes in 
phosphorylation. 
To examine the quantitation consistency of our approach, we applied this 
method to two non-phosphorylated Cdc13 peptides, 23-DFEGYPSK-30 and 567-
LELNEGFK-574.  These peptides are present in +2 and +3 charge states and 
come from different domains of the Cdc13 sequence. The results are presented 
in Supplementary Figure 2, where it is observed that the average ratio between 
these two peptides across several replicates is consistently close to 0.4 for 
asynchronous, G1 and G2/M phase cells. 
 
Telomere length determination 
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Mutations were introduced into the Cdc13 ORF using the Quick-Change site-
directed mutagenesis kit (Strategene). The mutations and ORF integrity were 
verified by DNA sequencing and then sub-cloned into a pRS314::CDC1329 (for 
Southern blot analysis) or a pRS314::Cdc13-myc9 plasmid (for Western blot 
analysis). Cells heterozygous for CDC13 (YPH501 cdc13!::HIS3/+) were 
transformed with pRS314::CDC13 or the mutant plasmids, sporulated, dissected, 
and genotypes determined by biosynthetic markers.  At least two independent 
isolates of each mutation were chosen for telomere length analysis using 
Southern blotting and/or for protein expression using Western blot analysis 
against the myc9 epitope. Freshly cleaved spores were struck three or more 
consecutive times on rich medium (YEPD) to reach the equilibrium telomere 
length. Genomic DNAs were digested with PstI and XhoI, separated on 0.8% 
agarose gels, transferred to Hybond N+ nylon membrane (GE Healthcare) and 
blotted with a randomly primed 32P-labled telomere probe isolated from pCT300.44 
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RESULTS 
Cdc13 is phosphorylated in vivo 
Structural, genetic and biochemical data have identified functional domains 
within Cdc13. In addition to the RD, Cdc13 consists of 4 oligosaccharide-
oligonucleotide binding (OB) folds (Figure 1A). The N-terminal OB1 (aa 14-225) 
is required for homodimerization,27,28 as well as for interaction with Pol1 (the 
largest subunit of DNA Pol!) and Sir4 (a silencing protein).28-30 OB3 (aa 497-693) 
is the canonical DNA binding domain (DBD).25,45 Functions of OB2 (aa 323-485) 
and OB4 (aa 712-924) are unclear but OB4 is implicated in Stn1 binding and its 
deletion results in telomere hyper-elongation.31,34 The RD (aa 190-340) is located 
between the OB1 and OB2 domains. 
Previously, we purified full-length Cdc13 from its native host, S. cerevisiae for 
functional studies and showed that yeast derived Cdc13 is highly active in ssDNA 
and Est1 binding.14 This purified Cdc13 migrated in SDS-PAGE gel as multiple 
bands (Figure 1B, lane 1). Treating purified Cdc13 with both " protein 
phosphatase and its metal cofactor MnCl2, but not with either one alone, 
converted all bands to a single, faster-migrating species (lanes 2-4), confirming 
that purified Cdc13 is phosphorylated. Since Cdc13 phosphorylation has been 
implicated in telomerase regulation,36-38 we decided to characterize its sites of 
phosphorylation in more detail. 
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Characterization of Cdc13 phosphorylation revealed previously unreported sites 
of modification 
There are 145 serines and threonines spread throughout the 924-amino acid 
Cdc13 ORF that are candidate sites for phosphorylation. We first identified 
Cdc13 phosphorylation sites by nano liquid chromatography tandem mass 
spectrometry (nanoLC-MS/MS) using protein affinity-purified from 
asynchronously growing cells (See Figure 2 and Materials and Methods for 
experimental design). Prior to nanoLC-MS/MS, purified Cdc13 was digested with 
either trypsin or LysC protease. Some post-translational modifications (PTMs), 
including phosphorylation are relatively labile, which can result in prompt loss 
during collision-induced dissociation (CID) fragmentation without further 
informative fragmentation of the modified peptide. Electron transfer dissociation 
(ETD) is a complementary alternative to CID in that it is a radical-based non-
ergotic process and does not convey levels of excess energy to the peptide as in 
CID, thereby minimizing prompt loss of labile species. However, due to 
coulombic forces, this approach increases in efficiency with longer peptide 
sequences bearing a higher total positive charge. Thus, we performed separate 
tryptic and LysC digests to obtain peptides of varying size and charge. Both 
digests were analyzed using either CID or ETD based on the decision-tree 
algorithm 46 (see Figure 2) to obtain a sufficient sampling of tandem MS for each 
fragmentation process.   It was discovered that ETD fragmentation for tryptic and 
LysC digests did not result in sufficient fragmentation for phosphorylation site 
localization, perhaps due to the relatively small size and charge states of the 
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peptides examined, so we consolidated the workflow to only tryptic digestion 
followed by CID fragmentation for the remainder of the study. 
In total, we identified 21 phosphorylation sites on full-length Cdc13 (Figure 3, 
Table 1). Five of these 21 sites (S225, S306, T308, S333, S336) were reported 
previously.36-38,40,47 Of these, one (S225) had not been confirmed to be present in 
vivo; and only two (S306 and T308) have been characterized for their biological 
function.37,38,40 When compared to the secondary structure of Cdc13 previously 
determined by x-ray crystallography or structural predictions,28 all 
phosphorylation sites map to positions on or immediately next to a loop, which 
are usually more flexible regions compared to ! helices or # strands.  
Strikingly, eleven of the 21 phosphorylation sites identified from the full-length 
Cdc13 were within a 128 aa region (S225 to S352) that overlaps both the RD and 
OB2 domain. In contrast, only two phosphorylation sites were mapped to OB1, 
and none was present within the DBD. The C-terminal OB4 domain was also 
phosphorylation-rich as it contained eight phosphorylation sites in two clusters 
(S708, T710, T711, S726, and S727 in one cluster and S883, S885, and T893 in 
the other). Despite repeated analytical attempts and exhaustive search of the 
resulting raw MS data, phosphorylation of the highly conserved RD core (N234 to 
D287).39 including the two previously identified in vitro Tel1/Mec1 targets, S249 
and S255,36 was not detected. 
 
Identification of phosphorylation sites from Cdc13 fragments 
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We also expressed two Cdc13 fragments in yeast: a.a. 1-340 (OB1-RD) and 
a.a. 445-697 (DBD) and determined phosphorylation sites within these fragments 
by nanoLC-MS/MS similarly as described for full-length Cdc13. From the OB1-
RD fragment, we could detect phosphorylation on all sites that were detected in 
the full-length Cdc13. We also detected two additional phosphorylation sites, T3 
and S170, which were not found in the full-length protein (Figure 3, Table 1). 
From the DBD fragment, we detected five additional sites that were not observed 
in the full-length Cdc13 (T458, S467, S472, T373, T507). Because three of the 
five sites identified from the DBD fragment are located in regions predicted to be 
in a # strand,28 we suspect that these five residues are buried within the interior 
of Cdc13 in the context of full-length protein; thus, their phosphorylation is 
unlikely to be biologically relevant. T3 is located at the distal N terminus and 
S170 maps to a disordered loop on the protein surface of the Cdc13 OB1 crystal 
structure.28 Hence both sites should be surface accessible in the OB1-RD 
fragment. Although we do not think this phosphorylation is biologically 
meaningful, the absence of S170 phosphorylation in the context of full-length 
protein suggests that the surface containing S170 may be involved in a long-
range interaction with another domain of Cdc13.  
 
Methods for analyzing the frequency of Cdc13 phosphorylation as a function of 
cell cycle progression 
Since telomerase action is strictly cell cycle regulated,9,10 key Cdc13 
phosphorylation events might be cell cycle regulated. To test this possibility, we 
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prepared Cdc13 from cells at two specific points in the cell cycle. Cells were 
arrested in ! factor (late G1 phase) when telomerase is not active or in 
nocodazole (G2/M phase) when telomerase is active.9,48 Cdc13 purified from 
specific cell cycle phases was subjected to enzymatic digestion and nanoLC-
MS/MS analyses to measure quantitatively changes in phosphorylation 
abundance between the two cell cycle stages.  We then used the algorithm 
described in the Methods section to determine sites of phosphorylation and 
perform relative quantitation between different modified forms of the same 
peptide.  A graphical summary of the phosphorylation levels for wild type Cdc13 
is presented (Figure 4). We quantified all alternatively cleaved peptides and 
graphed them separately, with the most consistently observed one listed first in 
each of the panels. 
Cdc13 Phosphorylation as a function of cell cycle position 
Out of all the peptides containing S306 and T308 (Figure 4A), the peptide 
302-SYIQSQTPER-311 was the most consistently observed. MS/MS analysis 
confirmed that the site of monophosphorylation on this peptide was preferentially 
T308, not S306 (data not shown). Monophosphorylation of this peptide was 
significantly higher in G2/M cells compared to G1 cells, a result consistent with 
previous reports that CDK1-dependent T308 phosphorylation occurs in S/G2 
phase.37,38 The diphosphorylated form of this peptide was also higher in G2/M 
cells compared to G1 cells, but this increase was not statistically significant. 
Of the monophosphorylated peptides containing S314 and S324 (Figure 4B), 
S314 was the dominant phosphorylation site. However, we also observed low 
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levels of S324 monophosphorylation within the 313-TSVPNNWHDDDSGSKR-
328 peptide. Phosphorylation of both S314 and S324 was significantly higher in 
G2/M cells compared to G1 cells.  
There is a strong grouping of potential phosphorylation sites (S333, S336, 
S340, S341) within the same peptides 331-KLSFHSPNASSIR-343 and 332-
LSFHSPNASSIR-343 (Figure 4C). S336 was the most abundant 
monophosphorylation mark, and its phosphorylation was relatively constant 
across the cell cycle. S341 is a novel site of Cdc13 phosphorylation that was only 
observed in peptide 331-KLSFHSPNASSIR-343 in conjunction with 
phosphorylation of both S333 and S336. This tri-phosphorylated peptide was not 
particularly abundant, but its abundance was significantly higher in protein from 
G2/M phase than from G1 phase cells.  
S347 was the major monophosphorylation site on peptide 345-
AISYEQLSLASVGSVER-361 (Figure 4D). Monophosphorylation of S352 was 
also detected, but its abundance was an order of magnitude lower than that of 
S347.  
Peptides 707-KSPTTPALAEHIPDLNADVSSFDVK-731 and 708-
SPTTPALAEHIPDLNADVSSFDVK-731 (Figure 4E) contained a cluster of 
phosphorylation sites (S708, T710, T711, S726, S727). NanoLC-MS/MS 
revealed that the most abundant modification in this region was 
monophosphorylation of S708, and this modification was modestly higher in G1 
phase. Diphosphorylated versions of this peptide were modified at S708 and 
either T710 or T711.  
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Lastly, low but consistent phosphorylation was observed on S883 on peptide 
877-VAAAPDSGSLDCAINATVNPLR-898 (Figure 4F). This phosphorylation did 
not change significantly across the cell cycle.  
It is important to note that for peptides containing more than one sites of 
phosphorylation, there are two possible issues that can complicate isoform 
quantitation.  The first is that the phosphopeptide isoforms are not 
chromatographically resolvable, resulting in ‘mixed’ tandem mass spectrum 
containing different percentages of each of the isobaric, co-eluting isoforms.  
Upon careful inspection of the annotated tandem mass spectra (Supplementary 
Figure 1), it was determined that this was not a limiting issue in our analysis.   In 
the second scenario, the peptides are chromatographically resolvable, resulting 
in two or more MS peaks in chromatogram corresponding to unique isoforms.  
We manually inspected the raw data for the existence of multiple 
chromatographic peaks consistent with distinct isobaric phosphopeptide 
isoforms, but did not find any in this study. 
 
Phosphorylation of Cdc13-E252K, a separation-of-function mutant that does not 
support telomerase action 
The high density of phosphorylation events in the RD/OB2 boundary was 
particularly interesting given the key role of the RD in telomerase regulation. To 
determine if any of the detected phosphorylated sites are associated with defects 
in telomerase recruitment, we purified full-length Cdc13-E252K, and analyzed it 
by nanoLC-MS/MS. All of the 21 phosphorylation sites seen in the full-length WT 
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Cdc13 were also detected in the mutant protein. Moreover, no new sites of 
phosphorylation were detected in Cdc13-E252K.  
We also investigated whether phosphorylation of Cdc13-E252K was cell cycle 
regulated in the same manner as WT Cdc13. We purified Cdc13-E252K from 
cells arrested in G1 phase with ! factor or in G2/M phase with nocodazole and 
subjected the purified proteins to enzymatic digestion and quantitative nanoLC-
MS/MS analysis as described for WT Cdc13 (see Figure 5 for a graphical 
summary of the WT-to-mutant ratio for each modified isoform).  
There were several significant differences in the pattern of cell cycle regulated 
phosphorylation in mutant versus WT protein. First, peptide 312-
KTSVPNNWHDDDSGSK-327 diphosphorylated on both S314 and S324 was 
>4,000-fold more abundant in WT protein from G2/M phase cells compared to 
G2/M phase Cdc13-E252K (Figure 5B). Second, peptide 332-LSFHSPNASSIR-
343 di-phosphorylated on S333 and S336 was 6.8-fold more abundant in WT 
protein from G1 phase cells compared to mutant protein from the same cell cycle 
phase (Figure 5C). We also observed a 129- and 56-fold decrease in the 
unphosphorylated form of peptide 331-KLSFHSPNASSIR-343 in WT protein 
compared to mutant protein in G1 and G2/M cell phases, respectively (Figure 
5C). In addition, we identified a small but significantly lower monophosphorylation 
of S347 in WT compared to peptides derived from the mutant protein across the 
cell cycle (Figure 5D). Additionally, S883 monophosphorylation was modestly 
downregulated in WT Cdc13 in G1 but upregulated in the G2/M phase of the cell 
cycle (Figure 5F).   
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Cdc13 S314 phosphorylation negatively affects telomere lengths 
Mutation of S225, S306, and S336 to a non-phosphorylatable residue was 
shown previously to have no effect on telomere length37-39 while a T308A 
mutation leads to modest reductions in both telomere length and Est1 telomere 
binding.37,38 Since phosphorylation of S314 and S324 was significantly higher in 
WT relative to Cdc13-E252K in G2/M phase, we decided to investigate the role of 
S314 and S324 phosphorylation in telomere length regulation. Using site directed 
mutagenesis, we changed S314 to either alanine (A), which cannot be 
phosphorylated, or to aspartate (D), a change that mimics constitutive 
phosphorylation. Mutant alleles were expressed from the Cdc13 promoter on a 
CEN plasmid in cells in which the mutant protein was the only version of Cdc13. 
Cells were grown for at least three consecutive restreaks, and genomic DNA was 
extracted for telomere length analysis. Strains expressing Cdc13-S314A, Cdc13-
S324A or Cdc13-S324D had WT length telomeres (Figure 6A, telomeres are on 
average 15 ± 3, 5 ± 1, 5 ± 1 bp longer than WT, respectively, n = 4). However, 
the S314D mutation led to stable but slightly shorter telomeres (37 ± 17 bp 
shorter than WT, n = 3) (Figure 6A, Table I). Moreover, the S314A S324A double 
mutant showed a synergistic effect that lead to telomeres 82 ± 30 bp longer than 
WT. The S314D S324D mutant, however, maintained telomeres 47 ± 14 bp 
shorter than WT, a length similar to that in the S314D mutant.  
To provide more evidence that phosphorylation at S314 affects telomere 
length, we introduced mutations at this residue into the cdc13-2 allele to generate 
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double mutants. Although the cdc13-2, S314A double mutant still senesced, its 
telomeres were on average 77 ± 21 bp longer compared to cdc13-2 alone (n = 3, 
Figure 6B). These differences were not due to effects of these mutations on 
protein abundance (Figure 6C). These results suggest that while phosphorylation 
of S324 is not important for telomere length, phosphorylation of S314A negatively 
regulates telomere length.
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DISCUSSION 
Misregulation of telomerase is associated with aging and cancer. 49 In 
budding yeast, telomerase is strictly controlled, occurring only in late S/G2 phase 
and acting preferentially on short telomeres. Cdc13 is a multi-functional telomere 
binding protein that acts as a type of molecular switch with its binding partners 
determining if it forms a protective cap (Stn1, Ten1), promotes telomerase 
elongation (Est1) or C-strand resynthesis (Pol !). Given its multiple binding 
partners and functions, Cdc13 is a good candidate for regulation by 
phosphorylation. 
We determined in vivo phosphorylation sites on both WT and the telomerase 
defective Cdc13-E252K protein in asynchronous, G1 arrested (telomerase 
inactive), and G2/M arrested (telomerase active) cells using a new label-free 
nanoLC-MS/MS approach to quantitate relative levels of phosphorylation at 
individual residues. This approach provides an alternative to methods that use 
internal peptide standards to provide absolute abundance of a given 
modification.50 Our approach is useful when, as with the project described here, 
the sites of phosphorylation are not known, since our label-free nanoLC-MS/MS 
method allows the simultaneous identification and relative abundance 
determination of phosphorylation sites. Relative abundance of a given 
modification was determined by comparing across samples (i.e., between WT 
and mutant Cdc13 or WT from G1 versus WT from G2/M phase cells) but never 
between different peptides. Estimating changes in relative abundances is valid 
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since the differences in ionization efficiency resulting from different PTMs on the 
same peptide sequence should be consistent across different runs. Indeed, our 
quantitative data were highly reproducible with small differences in relative 
abundances of modified residues across multiple technical and biological 
replicates (Figures 4, 5).  
Because our analysis was able to document modified isoforms that were 
present over a wide range of concentrations (Figure 4), this approach should be 
generally useful for analysis of other hyper-modified proteins. While 
identifications based on shotgun tandem MS and blind database searching only 
would have missed many lower abundance modifications, our method was able 
to identify these sites based on their relative retention time and MS isotopic 
distribution. If we had used only a traditional tandem MS search algorithm, we 
likely would have identified a large number of additional false sites of modification 
on the same peptide sequences because modified isoforms share a significant 
number of fragment ion peaks in tandem MS. Since our method simultaneously 
uses MS, MS2, and retention time to identify sites and degrees of 
phosphorylation, the false positive rate was low and even allowed discovery of 
sites in the absence of tandem MS. It should be noted here that all modified 
isoforms identified without available tandem MS were later targeted for MS2 in 
subsequent nanoLC-MS/MS runs to confirm their assignments. 
We identified 21 phosphorylation sites on the 924-amino acid Cdc13 
(summarized in Figure 3, Table 1). Of these 21 sites, 17 had not been detected 
previously in vivo (one of the 17 sites, S225, was seen on protein phosphorylated 
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in vitro36). All of the phosphorylation sites are located at residues predicted to be 
in flexible regions of Cdc13 that are more likely to be solvent accessible.28 In 
contrast, phosphorylation sites detected only in the Cdc13 DBD (S467, S472, 
T473) were not on exposed surfaces and probably are not relevant to intact 
protein. However, S170, a residue that was only phosphorylated in OB1-RD, is 
on a disordered loop28, indicating it is on the protein surface in the context of 
OB1-RD but not in the context of full-length Cdc13. Therefore, the S170-
containing surface may be responsible for a long-range interaction within the 
Cdc13 protein.  
The phosphorylated residues were not spread uniformly throughout the 
protein. To our surprise, regions that make critical biological contacts, such as 
the core of the DBD, OB1, and the highly conserved N-terminal half of RD that 
interacts with Est1 were devoid of detectable phosphorylation (Figure 3, Table 1). 
Perhaps the phosphorylation sites surrounding these interaction interfaces do not 
regulate these functions as an on-off switch like the phosphorylation sites on the 
CDKs 51,52. Rather, we suggest they are present to modulate and coordinate 
these interactions, or mediate long range interactions between Cdc13 domains.  
There was a cluster of ten phosphorylation sites within a 47 amino acid region 
at the boundary of the RD/OB2 domains (aa 306 to 352; Figure 3). This cluster 
includes the two previously identified phosphorylation sites (S306 and T308) and 
the one identified here (S314) whose phosphorylation affects telomere length or 
telomerase action (Figure 6). All three of these residues are located within the C-
terminal half of the RD. The extension of this phosphorylation cluster into the 
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OB2 domain suggests that OB2 may have a previously unidentified role in 
affecting telomerase recruitment in addition to its previously suggested roles as 
an effector of the affinity and sequence specificity of the DBD.53 
Of particular interest, phosphorylation of two in vitro identified Tel1/Mec1 
targets, S249 and S255 within the RD,36 was not detected despite repeated 
attempts. The lack of detectable phosphorylation on these two residues was 
probably not due to false negativity or low sensitivity from the search algorithms 
since we detected phosphorylation at two other Tel1/Mec1 sites, S225 and S306, 
as well as modifications present in ~ 0.01% of the sample (as in phosphorylation 
of 331-KLSFHSPNASSIR-343, Figure 4C). A lack of in vivo phosphorylation at 
these residues provides an explanation for seemingly contradictory results from 
earlier studies. S249 and S255 are both phosphorylated by Tel1 and Mec1 in 
vitro, and changing both residues to alanine confers a telomerase defective 
phenotype.36 Nonetheless, a cdc13-Q250A Q256A allele is not telomerase 
deficient.39 Our results support the interpretation that these residues are not 
Tel1/Mec1 substrates in vivo. Since these two SQ motifs are extremely 
conserved in Cdc13 from closely related fungi,28,39 we propose that they play a 
structural, rather than a signaling, role. In this model, the telomerase-null 
phenotype of the cdc13- S249A S255A allele is explained by a local loss of 
structural integrity rather than a lack of phosphorylation. These results 
emphasize the importance of determining sites of modification in vivo even when 
genetic data are available. 
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To gain information about the importance of phosphorylation of given 
residues, we determined if modifications were correlated with cell cycle phase 
(Figure 4) and/or WT versus telomerase deficient protein (Figure 5). There were 
no differences between mutant and WT protein in terms of sites of 
phosphorylation. This finding may indicate that regulated phosphorylation occurs 
upstream of telomerase recruitment. Alternatively, quantitative rather than 
qualitative differences in phosphorylation may explain functional differences as 
there were six sites that showed different levels of phosphorylation between WT 
and mutant Cdc13 (S314, S324, S333, S336, S347, S883). In addition, there 
were five residues (T308, S314, S324, S341, S708) that showed cell cycle-
specific differences. In both cases, these differences could be substantial. For 
example, phosphorylation of S314, S324 on the peptide 311-
KTSVPNNWHDDDSGSK-327 was 6-fold more abundant in WT protein in G2/M 
versus G1 phase (Figure 4B) and >4,000-fold less frequent in mutant Cdc13 
(Figure 5B). As the abundance of S314 phosphorylation was affected by both the 
cdc13-2 mutation and by the cell cycle, we mutated this site to alanine or 
aspartate. Although S314 mutations conferred effects on telomere length, 
consistent with phosphorylation at this residue having a negative effect on 
telomerase (Figure 6), the effects were subtle, similar to what has been seen 
previously for mutation of the Cdk1 target T308. 37,38 Thus, individual 
phosphorylation events may act redundantly to influence telomere length, and 
multiple mutations may be needed for large effects. Consistent with this view, we 
observed that the S314A S324A double mutation resulted in longer telomeres 
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while either mutation alone had no effect (Figure 6A). Our analysis provides 
many more candidates for residues that can be mutated singly and in 
combination with other mutations for effects on telomerase recruitment and 
telomere structure. 
CDK/MAPKs phosphorylate S/TP motifs and ATM/ATR kinases 
phosphorylate S/TQ motifs. There are seven S/TP and ten S/TQ motifs in Cdc13. 
Five of the seven S/TP motifs were phosphorylated in vivo, but only two were 
CDK1 targets in vitro. 37,38 Four of the ten S/TQ motifs can be phosphorylated by 
Tel1 or Mec1 in vitro, 36 but only two (S225, S306) appeared to be 
phosphorylated in vivo. Clearly factors other than sequence specificity contribute 
to substrate recognition and phosphorylation in vivo. The three S/TP motifs that 
are not direct CDK1 targets in vitro but were phosphorylated in vivo may be 
phosphorylated by another kinase with the same consensus motif. Indeed, the 
kinases responsible for most of the detected phosphorylation events (17 out of 
21) could not be determined by the sequence context of the modified residue. 
However, a recent high-throughput study identified three kinases, Cak1, Hsl1, 
and Vhs1, that affect cell cycle progression and that also interact with Cdc13.54 
All three are excellent candidates to explain phosphorylation of residues for 
which there is, as yet, no evident responsible kinase. 
This study has provided a wealth of knowledge about Cdc13 phosphorylation, 
but there is still much to learn. Although our study identified 17 novel 
phosphorylation sites, the biological functions of most of these are unknown. A 
full understanding of their importance will likely involve analysis of multiply 
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modified proteins to circumvent biological redundancy. By using information on 
the abundance of phosphorylation events as a function of the cell cycle and in 
vivo function, we provide a first step for a rational next stage analysis.
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TABLE LEGENDS 
Table 1. Summary of Cdc13 phosphorylation sites identified from full-
length, WT protein. The table indicates the position of phosphorylation, effect on 
telomere lengths, and change of abundance between cell cycle phases, and that 
between WT Cdc13 and the Cdc13-E252K mutant (MT). Sites from different 
domains are separated by dashed lines. Change in phosphorylation abundance 
for each site was derived from the most consistently observed peptide. Moderate, 
substantial, and drastic reflect a 2-5-fold, 5-10-fold, and more than 10-fold 
change in abundance. ND: not determined; a: result reported in a previously 
published work, 36 b, c: results reported in previously published works. 37,38  
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FIGURE LEGENDS 
FIGURE 1. (A) Schematic illustration of Cdc13 domain organization. (B) 
Phosphatase treatment of Cdc13. 1.5 µg of purified Cdc13 was incubated with 40 
U of " protein phosphatase (NEB, lanes 2, 3) and 1 mM MnCl2 (lanes 3, 4) in 1X 
vendor-supplied buffer at 30oC for 30 min. Samples were resolved on 8% SDS-
PAGE gel and stained with Coomassie blue.  
 
FIGURE 2. Schematic illustration of LC-MS/MS experimental and computational 
approach for phosphorylation identification and quantitation.  
 
FIGURE 3. Summary of Cdc13 phosphorylation sites with respect to domain 
structure.  
 
FIGURE 4. Cell cycle analysis of phospho-peptide levels from WT Cdc13. 
Results are presented as averages from at least two independent 
measurements. Error bars represent 1 standard deviation. Peptides that showed 
significant difference in abundance between G1 and G2/M phases are indicated 
by an asterisk. 
 
FIGURE 5. Comparison of phospho-peptide quantification between WT Cdc13 
and Cdc13-E252K mutant (MT). Results are presented as the Log2 value of the 
WT/MT ratio and the error bar represents 1 standard deviation. Peptides that 
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showed significant difference in abundance between WT and mutant are 
indicated by an asterisk. 
 
FIGURE 6. Telomere length analysis of Cdc13 phosphorylation mutants. cdc13$ 
cells carrying WT or mutant Cdc13 on a CEN TRP1 plasmid were analyzed for 
their telomere lengths as described in Methods. Mutants analyzed are (A) 
S314A, S314D, S324A, S324D, S314A S324A, and S314D S324D, and (B) 
cdc13-2 and cdc13-2 S314A mutants. (C) Western blot analysis of myc9-tagged 
Cdc13 mutants expressed from Cdc13 promoter on a CEN TRP1 plasmid (upper 
panel). The same blot was probed with anti-! tubulin as loading control (lower 
panel). UT: untagged. 
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Table 1. Summary of Cdc13 phosphorylation sites identified from full-
length, WT protein 
Position Flanking 
sequence Telomere length G1/G2 abundance WT/MT abundance Putative kinase 
S56 CLLGFSNFER ND ND ND  
S225 QKVLSQKSK Unchangeda ND ND  Tel1/Mec1a 
S306 KSYIQSQTPE Unchanged Unchanged Unchanged Mec1 a 
T308 KSYIQSQTPE T308A: slightly short b, c Moderate 
increase in 
G2/M 
Unchanged CDK1b, c 
S314 RKTSVPNNW S314A: slightly longer 
in cdc13-2 background 
S314D: slightly short 
Substantial 
increase in 
G2/M 
Drastic increase 
in WT in G2/M  
S324 DDDSGSKR S324A, S324D: 
unchanged Substantial increase in 
G2/M 
Drastic increase 
in WT in G2/M  
S333 KLSFHSPNAS ND Unchanged Drastic increase 
in WT in G1   
S336 KLSFHSPNAS S336A: unchangedb, c Unchanged Drastic increase 
in WT in G1  CDK1
b, c 
S340 FHSPNASSIR ND ND ND  
S341 SSIRKAISY ND Moderate 
increase in 
G2/M 
Unchanged   
S347 SSIRKAISY ND Unchanged Moderate 
decrease in WT  
S352 LSLASVGSVE ND ND ND  
S460 DKTASPGMA ND Unchanged Unchanged CDK/MAPK 
(not CDK1)
 b, c 
S708 VKHEPKKSPT S708A: slightly longer Moderate 
increase in G1 Unchanged CDK/MAPK (not CDK1) b, c 
S710 SPTTPALAE ND Unchanged Unchanged   
S711 SPTTPALAE T711A: unchanged  Unchanged Unchanged CDK/MAPK 
(not CDK1
 b, c
) 
S726 LNADVSSFD ND  ND ND  
S727 LNADVSSFD ND  ND ND  
S883 PDSGSLDCAI ND Unchanged Moderate 
decrease in WT 
in G1 but 
moderate 
increase in WT 
in G2/M 
 
S885 PDSGSLDCAI ND Unchanged Unchanged  
T893 NATVNPLRLL T893A, T893D: 
unchanged ND ND  
 






